Valeant Pharmaceuticals names Joseph Papa as Chairman and Chief Executive

He brings more than 30 years of leadership and operations experience in healthcare to the firm

Canadian firm Valeant Pharmaceuticals International has appointed Joseph C. Papa as Chairman and Chief Executive.

Papa joins Valeant from Perrigo, a developer, manufacturer and distributor of over-the-counter (OTC) and prescription (Rx) pharmaceuticals, where he was Chairman and Chief Executive. He will also join Valeant's Board of Directors and succeed J. Michael Pearson.

Papa has been CEO of Perrigo since 2006 and was appointed as Chairman of the Board of Directors of Perrigo in 2007. Prior to Perrigo, he was Chairman and Chief Executive of the Pharmaceutical and Technologies Services segment of Cardinal Health.

Earlier in his career, he was President and Chief Operating Officer of Watson Pharmaceuticals. Prior to this, Novartis and Pharmacia/Searle, he was responsible for overseeing the launches of Diovan, Celebrex and Lotrel.

You may also like

Finance

Sobi enters into new distribution agreement with Valeant for Ammonul

The company has entered into a three-year agreement with Valeant Pharmaceuticals Ireland for the distribution in Europe, the Middle East and North Africa
You need to be a subscriber to read this article.
Click here to find out more.
Media

A precision medicine approach to developing cancer vaccines

Modern anticancer medicines represent a significant improvement on one-size-fits-all chemotherapy, reports Dr Sarah Houlton
Design & Build

Valeant Canada expands with $27.5m investment

The company will expand manufacturing and exporting capacity in Steinbach, Manitoba and Laval, Quebec
Regulatory

Opinion: Politics, passion and patient power

Did political correctness play a greater role than therapeutic efficacy in the FDA's decision to approve the 'pink Viagra'?
Finance

Valeant Pharmaceuticals to acquire Synergetics USA

Acquisition will further enhance Bausch + Lomb's presence around the world in the rapidly evolving field of vitreoretinal surgery
Finance

Valeant Pharmaceuticals to buy Sprout Pharmaceuticals for US$1bn in cash

Acquires FDA-approved 'female Viagra' pill Addyi and enters female health sector
Finance

Valeant to acquire Amoun Pharmaceutical

Valeant intends for Amoun to serve as a platform for further expansion into the broader Middle East and North African pharmaceutical market
Subscribe now